BioTelemetry, Inc. (BEAT) Given Consensus Recommendation of “Hold” by Analysts

Shares of BioTelemetry, Inc. (NASDAQ:BEAT) have earned an average recommendation of “Hold” from the nine research firms that are covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating on the company. The average 1-year price objective among brokers that have covered the stock in the last year is $43.50.

BEAT has been the topic of several analyst reports. BidaskClub raised shares of BioTelemetry from a “strong sell” rating to a “sell” rating in a report on Tuesday, December 19th. Zacks Investment Research lowered shares of BioTelemetry from a “hold” rating to a “strong sell” rating in a report on Thursday, November 2nd. SunTrust Banks initiated coverage on shares of BioTelemetry in a report on Monday, October 23rd. They issued a “buy” rating and a $41.00 target price on the stock. Dougherty & Co reaffirmed a “buy” rating and issued a $40.00 target price on shares of BioTelemetry in a report on Wednesday, November 8th. Finally, Raymond James Financial initiated coverage on shares of BioTelemetry in a report on Thursday, October 26th. They issued an “outperform” rating and a $37.00 target price on the stock.

BioTelemetry (BEAT) traded up $0.90 on Tuesday, hitting $32.55. 284,500 shares of the stock traded hands, compared to its average volume of 418,293. The company has a current ratio of 1.60, a quick ratio of 1.48 and a debt-to-equity ratio of 0.75. BioTelemetry has a fifty-two week low of $23.30 and a fifty-two week high of $39.20. The company has a market cap of $1,025.72, a price-to-earnings ratio of 25.23, a price-to-earnings-growth ratio of 1.41 and a beta of 0.67.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Allianz Asset Management GmbH lifted its position in BioTelemetry by 23.1% during the 4th quarter. Allianz Asset Management GmbH now owns 526,211 shares of the medical research company’s stock worth $15,734,000 after buying an additional 98,752 shares in the last quarter. Cortina Asset Management LLC lifted its position in BioTelemetry by 37.8% during the 4th quarter. Cortina Asset Management LLC now owns 349,263 shares of the medical research company’s stock worth $10,443,000 after buying an additional 95,843 shares in the last quarter. Columbia Partners L L C Investment Management lifted its position in BioTelemetry by 30.1% during the 4th quarter. Columbia Partners L L C Investment Management now owns 71,051 shares of the medical research company’s stock worth $2,124,000 after buying an additional 16,453 shares in the last quarter. American International Group Inc. lifted its position in BioTelemetry by 11.4% during the 4th quarter. American International Group Inc. now owns 25,139 shares of the medical research company’s stock worth $752,000 after buying an additional 2,568 shares in the last quarter. Finally, BlackRock Inc. lifted its position in BioTelemetry by 7.4% during the 4th quarter. BlackRock Inc. now owns 4,093,837 shares of the medical research company’s stock worth $122,405,000 after buying an additional 281,415 shares in the last quarter. Institutional investors and hedge funds own 83.27% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was first published by American Banking News and is owned by of American Banking News. If you are accessing this report on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The original version of this report can be read at https://www.americanbankingnews.com/2018/02/13/biotelemetry-inc-beat-given-consensus-recommendation-of-hold-by-analysts.html.

About BioTelemetry

BioTelemetry, Inc (BioTelemetry), formerly CardioNet, Inc, provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting.

Analyst Recommendations for BioTelemetry (NASDAQ:BEAT)

Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply